Double-Duty drugs: new hope for Crohn's patients when standard treatment fails
NCT ID NCT06520397
Summary
This study is for adults with active Crohn's disease who are not getting better on their current standard dose of ustekinumab. It will test if adding a second drug (upadacitinib) works better and is as safe as simply giving a higher dose of the original drug. Researchers will compare the two approaches by checking gut health with scopes and monitoring symptoms and side effects over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wei Wang
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.